news search contents meditorial ask the doctor discuss register help home
The Doctor Will See You Now Navigation
Senior LivingWomen's HealthNutritionBioethicsBehaviorSpecialists

IN THIS ARTICLE

Current treatment

Diabetic eye disease

Nephrosis treatment

 Discussion


The Doctor's Health Tip
Very terrible pain in the abdomen is often the first sign of a gallstone. more...


OTHER TOPICS

When kidneys fail

Vitamin supplements


 Erythropoietin and Progressive Kidney Disease

Eli A. Friedman, M.D.

In a perfect world, every medical treatment would be backed up by solid science, that is, rigorous clinical trials. With well-designed trials, doctors and patients would know what treatments work best, how they work and why. In the world we live in, however, this level of scientific certainty is not always possible and, as a result, doctors must sometimes make treatment decisions based on personal experience or on sketchy or incomplete science.

The "off label" use of drugs to treat illnesses other than those for which they were approved or intended happens without scientific evidence of any benefit. We justify this by the desire to help patients for whom there are no scientifically established treatments. The use of penicillin for pneumonia is another example. No one questions that penicillin lowers the death rate in pneumococcal pneumonia, although no scientific studies to prove this have ever been done. But the alternative -- not using penicillin to treat pneumonia patients -- is unacceptable because the lives of untreated patients in the control ("placebo") group would be at risk.

A similar situation applies to the question of whether to give a synthetic hormone called erythropoietin to patients suffering from severe kidney ailments ("progressive renal disease"). These patients often are anemic, lacking sufficient red blood cells to carry oxygen from the lungs to the rest of the body. Doctors determine if you are anemic by calculating the hematocrit, the percentage of the blood that consists of blood cells, as opposed to plasma. A low hematocrit is a sign of anemia. Erythropoietin helps because it stimulates the bone marrow to make more red blood cells, thus raising the hematocrit. However, there have been no studies that prove that erythropoietin is safe and effective for those with progressive renal disease. Nevertheless, many doctors prescribe the drug for the anemia associated with kidney disease. In this article, we'll take a look at what we know and do not know about erythropoietin and kidney disease.

Current Kidney Treatments
Table 1 (below) shows the treaments that are most commonly used to slow down deterioration of the kidneys in people with kidney disease. Interestingly, only the first two, reducing high blood pressure and carefully treating diabetes, have been established as effective by clinical trials.

Table 1. Measures that Slow Progressive Renal17
  1. Bring down blood pressure18
  2. Maintain proper blood sugar levels (diabetes)19
  3. Limit dietary protein20
  4. Restrict dietary fat21
  5. Treat proteinuria (excess protein in the urine)22
  6. Stop smoking23
Table 2 lists the benefits of erythropoietin therapy for people with ESRD (End Stage Renal Disease), or those whose kidneys are actually failing.

Table 2. Benefits of Erythropoietin in Irreversible Renal Failure.24
  1. Enhanced brain function25
  2. Increased physical performance26
  3. Greatly improved quality of life27
  4. Prevention of a heart condition called progressive left ventricular dilatation28
  5. Reduced need for blood transfusions29
  6. Improved survival rate for those on hemodialysis/peritoneal dialysis30,31
There is a great deal of evidence that erythropoietin can help those with kidney failure1 One study found that treatment with erythropoietin before dialysis significantly increases survival rates in ESRD (End Stage Renal Disease).2 Based on this finding, most doctors now believe that erythropoietin therapy prior to ESRD treatment is a good idea.3

Erythropoietin in Nephrosis
Nephrosis, or nephrotic syndrome, is a condition that damages the blood-filtering parts (glomeruli) of the kidneys. More common in children under 9 years old, although it can occur at any age, nephrosis causes too much (or sometimes too little) protein to be released into the bloodstream which, in turn, produces water retention ("edema") most often noticed as swelling around the eyes, abdomen and legs. Anemia frequently occurs with nephrosis and studies on both adults and children indicate the superior effectiveness, compared to traditional treatments, of erythropoietin therapy.4,5

Erythropoietin in Diabetic Eye Disease
Early treatment with erythropoietin seems, in diabetic patients, to slow the onset of two eye conditions, diabetic retinopathy and macular edema, that can lead eventually, if untreated, to blindness.6-10 Erythropoietin treatment lessens the unwelcome effects of hypoxia (lower than normal levels of oxygen in the blood), a principal cause of diabetic eye disease.11-15

Table 3. Potential Value of Erythropoietin Pre-ESRD.
  1. Improves diabetic retinopathy (macular edema)
  2. Decreases stress on left ventricle
  3. Increases exercise tolerance
  4. Decreases fatigue and somnolence
  5. Enhances life quality
  6. Delays progression of renal disease
  7. Increases survival32

Conclusion
Today, most doctors agree that erythropoietin is an effective treatment for people with the anemia associated with progressive kidney disease. There is little question that erythropoietin can raise the level of the oxygen-carrying red blood cells (hematocrit) and have a beneficial effect. What is less certain is what hematocrit level doctors should shoot for and when to prescribe erythropoietin for patients with kidney disease. Based on what we know now, however, it seems that a hematocrit of 35-38% would be safe, effective, and in most cases, easy to attain.16

Erythropoietin therapy for those with progressive kidney disease, like any treatment that is not yet supported by the most rigorous possible scientific evidence, is in some ways a therapeutic gamble. There is always a chance that it may one day be discredited as ineffective or even harmful. On the other hand, the conservative "wait until proven" philosophy may deny a helpful -- or even life-saving -- therapy to an entire generation of patients.

November 2002 Email this article to a friend

References
1. Albertazzi A, Di Liberato L, Daniele F, Battistel V, Colombi L. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study. Int J Artif Organs 1998 ;21(1):12-8. return

2. Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001;37(2):348-55. return

3. Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 1999;10(8):1793-800. return

4. Feinstein S, Becker-Cohen R, Algur N, Raveh D, Shalev H, Shvil Y, Frishberg Y. Erythropoietin deficiency causes anemia in nephrotic children with normal kidney function. Am J Kidney Dis 2001;37(4):736-42. return

5. Ishimitsu T, Ono H, Sugiyama M, Asakawa H, Oka K, Numabe A, Abe M, Matsuoka H, Yagi S. Successful erythropoietin treatment for severe anemia in nephrotic syndrome without renal dysfunction. Nephron 1996;74(3):607-10. return

6. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001;24(3):495-9. return

7. Berman DH, Friedman EA. Partial absorption of hard exudates in patients with diabetic end-stage renal disease and severe anemia after treatment with erythropoietin. Retina 1994;14:1-5. return

8. Friedman EA, Brown CD, Berman DH. Erythropoietin in diabetic macular edema and renal insufficiency. Am J Kidney Dis 1995;26(1):202-8. return

9. Yun YS, Lee HC, Yoo NC, Song YD, Lim SK, Kim KR, Hahn JS, Huh KB. Reduced erythropoietin responsiveness to anemia in diabetic patients before advanced diabetic nephropathy. Diabetes Res Clin Pract 1999;46(3):223-9. return

10. Hadjadj S, Torremocha F, Fanelli A, Brizard A, Bauwens M, Marechaud R. Erythropoietin-dependent anaemia: a possible complication of diabetic neuropathy. Diabetes Metab 2001;27(3):383-5. return

11. Ozaki H, Hayashi H, Oshima K. Angiogenin levels in the vitreous from patients with proliferative diabetic retinopathy. Ophthalmic Res 1996;28:356-60. return

12. Obrosova IG, Stevens MJ, Lang HJ. Diabetes-Induced Changes in Retinal NAD-Redox Status. pharmacological modulation and implications for pathogenesis of diabetic retinopathy. Pharmacology 2001 ;62(3):172-80. return

13. Kissun RD, Garner A. Vasoformative properties of normal and hypoxic retinal tissue. Br J Ophthalmol 1977;61(6):394-8. return

14. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Miller JW, Adamis AP, Aiello LP. Diabetes Metab Rev 1997;13(1):37-50. return

15. Clermont AC, Aiello LP, Mori F, Aiello LM, Bursell SE. Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy. Am J Ophthalmol. 1998;125:731-2. return

16. Nissenson AR. Optimal hematocrit for hemodialysis. Curr Opin Nephrol Hypertens 1997;6(6):524-7. return

17. Basta E, Bakris GL.. Evolution of drugs that preserve renal function. J Clin Pharmacol 2000;40:978-89. return

18. Cinotti GA, Zucchelli PC; Collaborative Study Group. Nephrol Dial Transplant. Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies.2001;16(5):961-6. return

19. Chase HP, Lockspeiser T, Peery B, Shepherd M, MacKenzie T, Anderson J, Garg SK. The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes. Diabetes Care 2001;24(3):430-4. return

20. Fouque D, Wang P, Laville M, Boissel JP. Low protein diets for chronic renal failure in non diabetic adults Cochrane Review). Cochrane Database Syst Rev 2001;2:CD001892. return

21. Schmitz PG. Progressive renal insufficiency. Office strategies to prevent or slow progression of kidney disease. Postgrad Med 2000 Jul;108(1):145-8, 151-4. return

22. Keane WF. Am J Kidney Dis 2000;35(4 Suppl 1):S97-105. Proteinuria: its clinical importance and role in progressive renal disease. return

23. Righetti M, Sessa A. Cigarette smoking and kidney involvement. J Nephrol 2001;14(1):3-6. return

24. Murphy ST, Parfrey PS. Erythropoietin therapy in chronic uremia: the impact of normalization of hematocrit. Curr Opin Nephrol Hypertens 1999;8(5):573-8. return

25. Macdougall IC. Quality of life and anemia: the nephrology experience. Semin Oncol 1998;25(3 Suppl 7):39-42. return

26. Johansen KL. Physical functioning and exercise capacity in patients on dialysis. Adv Ren Replace Ther 1999;6(2):141-8. return

27. Brandberg Y. Quality of life in clinical trials: assessment and utility with special reference to rHuEPO. Med Oncol 1998;15 Suppl 1:S8-12. return

28. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000 Sep;15:1425-30. return

29. Page DE, House A. Important cost differences of blood transfusions and erythropoietin between hemodialysis and peritoneal dialysis patients. Adv Perit Dial 1998;14:87-9. return

30. Mocks J. Cardiovascular mortality in haemodialysis patients treated with epoetin beta - a retrospective study. Nephron 2000;86(4):455-62. return

31. Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol 2000;20(4):345-9. return

32. Macdougall IC. How to improve survival in pre-dialysis patients. Nephron 2000;85 Suppl 1:15-22. return



  

  NEWS   SEARCH   CONTENTS   MEDITORIAL   ASK   DISCUSS   REGISTER   HELP   HOME 

© 2008 interMDnet Corporation. All Rights Reserved.  PRIVACY POLICY